Faculty

David M. Routman, M.D.

Clinical Studies

MC200710 Stimulating Immune Response with Neoadjuvant Human Papilloma Virus (HPV)-16 specific Vaccination in HPV-Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC) Rochester, Minn.
Some patients with head and neck cancer caused by human papilloma virus have a higher risk of recurrence. We are proposing to treat these patients with HPV vaccine with or without pembrolizumab during the window prior to surgery, in hopes of stimulating an immune response.

DART 2.0: ctHPV-DNA Informed De-Escalated Adjuvant and Definitive Radiation Therapy (GMROR2271) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.
The primary goal of this study is to prospectively incorporate ctHPVDNA in combination with clinical and pathologic factors to appropriately select patients for treatment intensity.